South Korea
· Delayed Price · Currency is KRW Pharos iBio Statistics
Total Valuation
Pharos iBio has a market cap or net worth of KRW 128.16 billion. The enterprise value is 108.84 billion.
| Market Cap | 128.16B |
| Enterprise Value | 108.84B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharos iBio has 12.92 million shares outstanding. The number of shares has increased by 24.45% in one year.
| Shares Outstanding | 12.92M |
| Shares Change (YoY) | +24.45% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 33.52% |
| Owned by Institutions (%) | 17.69% |
| Float | 8.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.60 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.37 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.38 |
Financial Position
The company has a current ratio of 25.90, with a Debt / Equity ratio of 0.01.
| Current Ratio | 25.90 |
| Quick Ratio | 25.28 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -1,316.47 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -317.97M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.18% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.18% |
| 50-Day Moving Average | 10,108.80 |
| 200-Day Moving Average | 13,013.80 |
| Relative Strength Index (RSI) | 54.07 |
| Average Volume (20 Days) | 160,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -22.75M |
| Operating Income | -12.27B |
| Pretax Income | -10.49B |
| Net Income | -10.49B |
| EBITDA | -11.51B |
| EBIT | -12.27B |
| Earnings Per Share (EPS) | -818.56 |
Balance Sheet
The company has 19.51 billion in cash and 201.12 million in debt, giving a net cash position of 19.31 billion or 1,494.99 per share.
| Cash & Cash Equivalents | 19.51B |
| Total Debt | 201.12M |
| Net Cash | 19.31B |
| Net Cash Per Share | 1,494.99 |
| Equity (Book Value) | 22.87B |
| Book Value Per Share | 1,770.56 |
| Working Capital | 19.52B |
Cash Flow
In the last 12 months, operating cash flow was -9.56 billion and capital expenditures -923.79 million, giving a free cash flow of -10.49 billion.
| Operating Cash Flow | -9.56B |
| Capital Expenditures | -923.79M |
| Free Cash Flow | -10.49B |
| FCF Per Share | -811.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pharos iBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.45% |
| Shareholder Yield | -24.45% |
| Earnings Yield | -8.25% |
| FCF Yield | -8.18% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |